Why it Matters
Coherus Biosciences Inc. has increased its in-house lobbying activities, spending $125,000 in Q2 2025. This shift from using external firms to an in-house approach indicates their focus on tailoring lobbying efforts amid shifting legislation affecting pharmaceuticals.
By the Numbers
Coherus has invested $125,000 in its Q2 in-house lobbying efforts. The in-house strategy grants them consistency, cost control, and swift responsiveness. David T. Sanders, with extensive pharmaceutical lobbying experience, is leading these efforts.
Why Now
Key legislative and geopolitical shifts drive Coherus’s current lobbying. The ongoing implementation of the Inflation Reduction Act (IRA) affects pricing for biosimilars. Additionally, the BIOSECURE Act and domestic manufacturing incentives reflect significant industry changes.
The Agenda
Coherus focuses on issues like IRA implementation, domestic drug production, supply chain security, and the BIOSECURE Act. They aim to ensure the biosimilar market remains competitive amid policy changes.
Competitive Landscape
No other competitors’ lobbying activities are currently available. Coherus stands uniquely focused on shaping the legislative environment around biosimilars and domestic production.
Between The Lines
The political climate around drug pricing reforms, national security, and pandemic-induced supply chain concerns influences Coherus’s agenda. Current policies in Congress, like IRA and the BIOSECURE Act, create an environment ripe for lobbying.
The Bottom Line
Coherus is strategically amplifying its in-house lobbying to navigate complex legislative landscapes affecting biosimilar development and commercialization. Their efforts underscore the importance of active engagement in shaping pharmaceutical industry policies.
Spot something wrong? Report an issue with this article